Short Bowel Syndrome Global Market Report 2025

Description

Short bowel syndrome (SBS) is a malabsorption disorder that occurs due to the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. This often results in symptoms such as diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of these symptoms depends on the length of the remaining intestine and its ability to adapt. SBS can have a major impact on overall health, requiring careful dietary and medical management.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of treatments in short bowel syndrome include glucagon-like peptide (GLP-2), growth hormone, and glutamine. GLP-2, an intestinal hormone, plays a vital role in enhancing nutrient absorption, promoting intestinal growth, and reducing inflammation in the gut, making it a key focus for therapeutic approaches in conditions such as SBS. Diagnosis involves physical exams, blood tests, fecal fat tests, imaging procedures, and other assessments. Treatment options include nutritional therapy, medications, surgery, and transplants, which are provided through various channels such as hospital pharmacies, specialty pharmacies, and others.

The short bowel syndrome market research report is one of a series of new reports from The Business Research Company that provides short bowel syndrome market statistics, including short bowel syndrome industry global market size, regional shares, competitors with a short bowel syndrome market share, detailed short bowel syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the short bowel syndrome industry. This short bowel syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The short bowel syndrome market size has grown rapidly in recent years. It will grow from$2.69 billion in 2024 to $3.09 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of gastrointestinal disorders, rising healthcare spending and expanded insurance coverage, advancements in post-surgical management of SBS, a higher incidence of Crohn's disease and other gastrointestinal disorders, and improvements in parenteral nutrition formulations and administration techniques.

The short bowel syndrome market size is expected to see rapid growth in the next few years. It will grow to$5.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth projected for the forecast period can be attributed to several factors, including the rising prevalence of short bowel syndrome (SBS), increasing adoption of parenteral and enteral nutrition therapies, expanding clinical research and drug development, higher healthcare expenditure, and greater awareness and early diagnosis of SBS. Key trends in the forecast period include advancements in intestinal rehabilitation therapies, the development of small intestine transplantation techniques, the adoption of telemedicine for SBS management, technological innovations in enteral feeding devices, and the integration of artificial intelligence in SBS treatment planning.

The increasing prevalence of gastrointestinal diseases is expected to drive the growth of the short bowel syndrome market in the coming years. Gastrointestinal diseases encompass a wide range of conditions affecting the digestive tract, including the stomach, intestines, liver, and pancreas, often impairing digestion and nutrient absorption. The rise in these diseases is largely driven by unhealthy dietary habits that disrupt gut health and promote inflammation. Gastrointestinal disorders can contribute to short bowel syndrome by requiring surgical removal of damaged intestinal sections, which reduces the intestine's ability to absorb nutrients. For instance, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre reported that over 320,000 people in Canada have inflammatory bowel disease (IBD), and the prevalence is expected to increase by 2.44% annually. By 2035, an estimated 470,000 Canadians will be living with IBD. Consequently, the growing prevalence of gastrointestinal diseases is boosting the growth of the short bowel syndrome market.

Key players in the short bowel syndrome market are focusing on developing cutting-edge treatments for intestinal failure to improve outcomes for patients with gastrointestinal disorders. Intestinal failure is a serious condition where the small intestine is unable to absorb sufficient nutrients, fluids, and electrolytes, compromising hydration and nutrition. For example, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, presented new data from studies on apraglutide, a next-generation GLP-2 analog, in adults with short bowel syndrome and intestinal failure. Apraglutide showed potential to enhance intestinal absorption and reduce dependence on parenteral support, highlighting the drug's safety, efficacy, and long-term benefits. This advancement underscores Ironwood's dedication to developing innovative therapies for gastrointestinal disorders.

In May 2024, Takeda Pharmaceutical Company Limited, a Japan-based global pharmaceutical company, partnered with Inspire, a US-based patient community platform, to address the unmet needs of short bowel syndrome patients. This collaboration aims to use real-world patient insights and multidisciplinary research to identify care gaps, improve patient support, and drive innovation in treatment approaches for short bowel syndrome. Inspire connects patients with health and wellness communities to enhance patient engagement and support data-driven solutions for healthcare challenges.

Major players in the short bowel syndrome market are Nestle SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc., Adocia SAS, EnteraBio Ltd, and GLyPharma Therapeutic Inc.

North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short bowel syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short bowel syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short bowel syndrome market consists of revenues earned by entities by providing services such as medical care, diagnostic testing, nutritional support, and ongoing patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The short bowel syndrome market also includes sales of oral rehydration solutions, antidiarrheal medications, proton pump inhibitors, antimotility agents, bile acid binders, antimicrobials, and specialized enteral nutrition formulas. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short Bowel Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on short bowel syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for short bowel syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The short bowel syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine
2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis
3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels
Subsegments:
1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues
2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies
3) By Glutamine: Oral Glutamine; Intravenous Glutamine
Companies Mentioned: Nestle SA; Pfizer Inc; Johnson & Johnson; Sanofi SA; Nutrinia
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34967

1. Executive Summary

2. Short Bowel Syndrome Market Characteristics

3. Short Bowel Syndrome Market Trends And Strategies

4. Short Bowel Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Short Bowel Syndrome Growth Analysis And Strategic Analysis Framework

5.1. Global Short Bowel Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Short Bowel Syndrome Market Growth Rate Analysis
5.4. Global Short Bowel Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Short Bowel Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Short Bowel Syndrome Total Addressable Market (TAM)

6. Short Bowel Syndrome Market Segmentation

6.1. Global Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glucagon-Like Peptide (GLP-2)
Growth Hormone
Glutamine
6.2. Global Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Physical Exam
Blood Tests
Fecal Fat Tests
Imaging Procedures
Other Diagnosis
6.3. Global Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nutritional Therapy
Medications
Surgery
Transplant
6.4. Global Short Bowel Syndrome Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Specialty Pharmacies
Other Distribution Channels
6.5. Global Short Bowel Syndrome Market, Sub-Segmentation Of (Glucagon-Like Peptide) GLP-2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Teduglutide
Other GLP-2 Analogues
6.6. Global Short Bowel Syndrome Market, Sub-Segmentation Of Growth Hormone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Somatropin
Other Growth Hormone Therapies
6.7. Global Short Bowel Syndrome Market, Sub-Segmentation Of Glutamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Glutamine
Intravenous Glutamine

7. Short Bowel Syndrome Market Regional And Country Analysis

7.1. Global Short Bowel Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Short Bowel Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Short Bowel Syndrome Market

8.1. Asia-Pacific Short Bowel Syndrome Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Short Bowel Syndrome Market

9.1. China Short Bowel Syndrome Market Overview
9.2. China Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Short Bowel Syndrome Market

10.1. India Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Short Bowel Syndrome Market

11.1. Japan Short Bowel Syndrome Market Overview
11.2. Japan Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Short Bowel Syndrome Market

12.1. Australia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Short Bowel Syndrome Market

13.1. Indonesia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Short Bowel Syndrome Market

14.1. South Korea Short Bowel Syndrome Market Overview
14.2. South Korea Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Short Bowel Syndrome Market

15.1. Western Europe Short Bowel Syndrome Market Overview
15.2. Western Europe Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Short Bowel Syndrome Market

16.1. UK Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Short Bowel Syndrome Market

17.1. Germany Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Short Bowel Syndrome Market

18.1. France Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Short Bowel Syndrome Market

19.1. Italy Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Short Bowel Syndrome Market

20.1. Spain Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Short Bowel Syndrome Market

21.1. Eastern Europe Short Bowel Syndrome Market Overview
21.2. Eastern Europe Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Short Bowel Syndrome Market

22.1. Russia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Short Bowel Syndrome Market

23.1. North America Short Bowel Syndrome Market Overview
23.2. North America Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Short Bowel Syndrome Market

24.1. USA Short Bowel Syndrome Market Overview
24.2. USA Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Short Bowel Syndrome Market

25.1. Canada Short Bowel Syndrome Market Overview
25.2. Canada Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Short Bowel Syndrome Market

26.1. South America Short Bowel Syndrome Market Overview
26.2. South America Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Short Bowel Syndrome Market

27.1. Brazil Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Short Bowel Syndrome Market

28.1. Middle East Short Bowel Syndrome Market Overview
28.2. Middle East Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Short Bowel Syndrome Market

29.1. Africa Short Bowel Syndrome Market Overview
29.2. Africa Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Short Bowel Syndrome Market Competitive Landscape And Company Profiles

30.1. Short Bowel Syndrome Market Competitive Landscape
30.2. Short Bowel Syndrome Market Company Profiles
- 30.2.1. Nestle SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Nutrinia Overview, Products and Services, Strategy and Financial Analysis

31. Short Bowel Syndrome Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Zealand Pharma
31.4. Baxter International Inc.
31.5. Alnylam Pharmaceuticals
31.6. OPKO Health Inc
31.7. Ironwood Pharmaceuticals Inc.
31.8. Hanmi Pharm Co. Ltd
31.9. Ardelyx Inc
31.10. Emmaus Life Sciences Inc
31.11. Jaguar Health
- 31.12. 9 Meters Biopharma Inc.
31.13. OxThera Inc.
31.14. Adocia SAS
31.15. EnteraBio Ltd

32. Global Short Bowel Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short Bowel Syndrome Market

34. Recent Developments In The Short Bowel Syndrome Market

35. Short Bowel Syndrome Market High Potential Countries, Segments and Strategies

35.1 Short Bowel Syndrome Market In 2029 - Countries Offering Most New Opportunities
35.2 Short Bowel Syndrome Market In 2029 - Segments Offering Most New Opportunities
35.3 Short Bowel Syndrome Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34967_Short_Bowel_Syndrome_GMR_2025